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Abstract Antimicrobial peptides (AMPs) are components of
the innate immune system in many species of animals. Their
diverse spectrum of activity against microbial pathogens, both
as innate defense molecules and immunomodulators, makes
them attractive candidates for the development of a new gen-
eration of antibiotics. Although the potential immunogenicity
of AMPs means they are not suitable for injection and their
susceptibility to digestive peptidases is likely to reduce their
oral efficacy, they are ideal for topical formulations such as
lotions, creams, shampoos, and wound dressings and could
therefore be valuable products for the cosmetic industry. In
this context, short AMPs (<20 amino acids) lacking disulfide
bonds combine optimal antimicrobial activity with inexpen-
sive chemical synthesis and are therefore more compatible
with large-scale production and the modifications required to
ensure stability, low toxicity, and microbial specificity. Proof-
of-concept for the application of AMPs as novel anti-
infectives has already been provided in clinical trials. This
perspective considers the anti-infective properties of short
AMPs lacking disulfide bonds, which are active against
dermatologically important microflora. We consider the chal-
lenges that need to be addressed to facilitate the prophylactic
application of AMPs in personal care products.
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Introduction
Animals are covered in protective layers of cells and their
secretions, providing a semi-permeable environmental barrier
colloquially described as Bskin^. In humans, the skin is the
first line of defense against continuous assault by a diverse
range of microbes, some of which are able to cause severe
dermatological diseases, especially in immunocompromised
patients (Table 1). The innate immune response in most ani-
mal species includes the synthesis of antimicrobial peptides
(AMPs) that can kill microbes by contact, suppress their
growth, or act as immunomodulators (Bolouri Moghaddam
et al. 2015; Rahnamaeian et al. 2009; Vilcinskas 2011). Hun-
dreds of AMPs have been discovered with overlapping activ-
ity spectra against different classes of pathogen (including
viruses, bacteria and fungi), and this makes them attractive
candidates for the development of novel antimicrobials. Be-
cause they are peptides, they are unlikely to be suitable for
injection (due to potential immunogenicity) or oral adminis-
tration (due to peptidase sensitivity) without significant mod-
ification (Wiesner and Vilcinskas 2010), leaving topical appli-
cation as the one remaining option. Humans naturally produce
AMPs in the skin, so the addition of further AMPs with
broader activity could be developed as a therapeutic interven-
tion for the treatment of skin diseases and also a prophylactic
strategy in the cosmetic industry to deter pathogens and pro-
mote skin health. This could be realized in topical formula-
tions such as ointments, lotions, shampoos, creams, or wound
dressings targeting skin pathogens and avoiding the complex-
ities of systemic anti-infectives (Table 2).
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Table 1 Dermatological diseases, corresponding pathogens and relevant AMPs
Disease Microbial agent Region of infection Active AMPs Reference
Folliculitis Staphylococcus aureus Hair follicles UBI Brouwer et al. 2006
TsAP-2 Guo et al. 2013
NRC-16 Gopal et al. 2013
Epinecidin 4 & 5 & 6 & 7 & 8 Lin et al. 2013
PE1 & PE2 Huang et al. 2013
HM2 & HM5 Park et al. 2004
Ranalexin Aleinein et al. 2013
Plc-2 Souza et al. 2013
Hot tub folliculitis Pseudomonas aeruginosa Hair follicles Stylisin 2 Dahiya & Gautam, 2010
NRC-16 Gopal et al. 2013
PE1 & PE2 Huang et al. 2013
Plc-2 Souza et al. 2013
Impetigo Staphylococcus aureus Skin See above See above
Staphylococcus pyogenes Ranalexin Aleinein et al. 2013
Dermatophytosis Microsporum audouinii Skin Stylisin 2 Dahiya & Gautam, 2010
Microsporum gypseum Tachyplesin III Simonetti et al. 2009
White piedra Trichosporon beigelii Hair HM2 & HM5 Huang et al. 2013
Rev-NIS Lee & Lee 2009
Seborrheic dermatitis Malassezia furfur Scalp, face, torso P5 Ryu et al. 2011
Rev-NIS Lee & Lee 2009
Onychomycosis Trichophyton rubrum Nail Cryptocandin Stobel et al. 1999
Tachyplesin III Simonetti et al. 2009
Trichophyton mentagrophytes Nail Stylisin 2 Dahiya & Gautam 2010
A12-C Gálvez et al. 1993
Cryptocandin Stobel et al. 1999
Tachyplesin III Simonetti et al. 2009
Athlete’s foot (tinea pedi) Trichophyton rubrum Foot See above See above
Intertrigo Candida albicans Body folds Stylisin 2 Dahiya & Gautam 2010
TsAP-2 Guo et al. 2013
HM2 & HM5 Park et al. 2004
Cryptocandin Stobel et al. 1999
Ranalexin Aleinein et al. 2013
Rev-NIS Lee & Lee 2009
Jock itch/tinea cruris Trichophyton rubrum Groin See above See above
Ringworm—tinea corporis Trichophyton rubrum Glabrous skin See above See above
Microsporum canis A12-C Gálvez et al. 1993
Tachyplesin III Simonetti et al. 2009
Trichophyton mentagrophytes See above See above
Tinea versicolor Malassezia furfur Trunk and proximal
extremities









Tinea barbae Trichophyton mentagrophytes Hair and beard See above See above
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The production of AMPs as cosmetic ingredients would
require large-scale production, placing the focus on properties
such as peptide length and structure. AMPs longer than 20
amino acids would be too expensive for routine chemical syn-
thesis, and the requirement for disulfide bonds would intro-
duce additional folding steps that would also increase the costs
of production. Short AMPs are less immunogenic and would
therefore be less likely to trigger allergies (Dhiraj et al. 2006),
and they would be easier to modify to increase stability, re-
duce toxicity, or engineer microbial specificity. It is worthy to
note that the selection of an appropriate formulation for AMP-
based topical products has a substantial impact on their effi-
cacy (Trotti et al. 2004; Kollef et al. 2006; van Saene et al.
2007) as shown for the treatment of oral mucositis, in which a
mucosal-adhesive paste is superior to a mouthwash (van
Saene et al. 2007).
In this perspective, we discuss the antimicrobial prop-
erties of short AMPs (fewer than 20 residues, and no
disulfide bonds) that are active against dermatologically
relevant pathogens as cosmetic ingredients. We discuss
the requirements that must be met for their prophylactic
application in personal care products. However, we do
not include the development of AMPs targeting Acne
vulgaris, which has been comprehensively discussed in
other articles (Fisk et al. 2014; Howard 2014; Cresce
et al. 2014; Bartlett et al. 2014; Rocha et al. 2014;
Zouboulis 2014).
Naturally occurring AMPs in human skin
Like other animals, humans naturally produce AMPs in
the skin to deter pathogens. These self-peptides are suit-
able candidates for development as cosmetic ingredients
because they would be the least likely to cause off-
target effects. Human skin AMPs include β-defensin
(hBD-2), RNase7, and psoriasin, which are active
against different ranges of skin pathogens. The antimi-
crobial activities of these peptides have been compared
to the antibiotic fluconazole against the germinating co-
n id i a o f Tr i chophy ton rubrum , Tr i chophy ton
mentagrophytes , Epidermophyton floccosum, and
Microsporum canis, revealing that all three AMPs sig-
nificantly inhibited fungal growth although with variable
efficacy depending on the AMP/pathogen combination.
E. floccosum was suppressed by all three AMPs, where-
as M. canis was only inhibited by psoriasin, but in the
latter case, the inhibitory effect was greater than flucon-
azole (Fritz et al. 2012). Unfortunately, all three of the
AMPs discussed above exceed 20 amino acids in length
or contain disulfide bonds, which would increase the
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AMP-derived core fragments and their activity
against skin pathogens
Although natural human AMPs may be too long or complex
for chemical synthesis, the entire AMP might not be required
because the antimicrobial activity resolves to a smaller essen-
tial motif. This shorter derivative might show the same effica-
cy as the parent peptide but would be easier to synthesize.
Several reports describe the engineering of AMPs to retain
or even improve their efficacy while reducing their length as
much as possible. One example is UBI, an eight-residue syn-
thetic peptide representing residues 31–38 of the 59-residue
full-length AMP ubiquicidin, which retains full activity
against methicillin resistant Staphylococcus aureus (Brouwer
et al. 2006). Likewise, Lin et al. (2013) synthesized a series of
truncated AMPs (anti-lipopolysaccharide factor from shrimp,
epinecidin from grouper, and pardaxin from Pardachirus
marmoratus) to look for shorter stretches of sequences that
increase antimicrobial potency. As a result, epinecidin-8 and
pardaxin-6 showed a broad range of activity against both
Gram-positive and Gram-negative bacteria, with no induction
of hemolysis. The same is true for Plc-2 which is a 12-residue
C-terminal fragment of pleurocidin and the smallest fragment
that retains the antimicrobial potency of the original peptide.
Based on MIC values determined in vitro with low-ionic-
strength medium, Plc-2 was active against S. aureus,
Escherichia coli, and Pseudomonas aeruginosa but not
against Enterococcus faecalis. The antifungal activity of the
synthetic peptides against plant pathogens such as Fusarium
oxysporum andColletotrichum sp. were shown to bemediated
by the lysis of organelle membranes (Souza et al. 2013).
Engineering of AMPs to maximize antimicrobial
activity and minimize hemolytic effect
One concern regarding AMPs is their possible hemolytic ef-
fects at higher concentrations, which necessitates their
targeted engineering to (i) improve their antimicrobial activity
and (ii) reduce their hemolytic effects. Generally, an increase
in positive charge increases the antimicrobial activity whereas
an increase in hydrophobicity causes a hemolytic effect (Park
et al. 2004). The configurational stereochemistry (D or L en-
antiomers) of specific amino acids may also affect hemolytic
activity (Roy et al. 2002). In an attempt to trim AMPs by Lys-
substitution to improve their net charge, Park et al. (2004)
produced the peptides HM2 and HM5, which showed antimi-
crobial activity against S. aureus, Trichospora beigelii and
Candida albicans but no hemolytic activity in the range of
0.78–50 μM. In another study, Guo et al. (2013) tested two
17-mer amidated linear peptides (TsAP-1 and TsAP-2) isolat-
ed from the Brazilian yellow scorpion (Tityus serrulatus) and
found they have distinct antimicrobial properties. TsAP-1 was
less active than TsAP-2 against E. coli, S. aureus, and
C. albicans with minimal inhibitory concentrations (MICs)
of 120–160 μM and hemolytic activity of 6.48 % at
160 μM, whereas TsAP-2 showed potent activity against
S. aureus (MIC =5 μM) and C. albicans (MIC = 10 μM) with
almost no hemolytic activity at ≤15 μM but strong hemolytic
activity thereafter. The replacement of four neutral amino acid
residues in each peptide with lysine residues had a dramatic
effect on their antimicrobial and hemolytic activities, particu-
larly those of TsAP-1. The MIC values for the enhanced cat-
ionic analog (TsAP-S1) fell to 2.5 μM for S. aureus and
C. albicans and 5 μM for E. coli, but the hemolytic activity
increased to a maximum of 28 % at 5 μM. The same lysine
residue substitutions in TsAP-2 reduced itsMIC against E. coli
from >320 to 5 μM, but the hemolytic activity remained as
high as TsAP-S1 (Guo et al. 2013).
AMPs promising for the skin infections and atopic
eczema
C. albicans can cause skin infections and atopic eczema, char-
acterized by the accumulation of neutrophils culminating in
inflammatory responses and the secretion of enzymatic pro-
teins. High-molecular-weight kininogen (HK) then triggers
the formation and release of AMPs to interfere with the estab-
lishment of pathogenesis. Highly potent antifungal peptide
fragments are produced via the proteolytic degradation of
HK (Sonesson et al. 2011). Lipophilic yeasts of the genus
Malassezia cause seborrheic dermatitis, resulting in the colo-
nization of infected skin by Malassezia furfur, Malassezia
globosa, Malassezia restricta, Malassezia slooffiae,
Malassezia sympodialis , or Malassezia obobtusa
(Nakabayashi et al. 2000). Especially,M. furfur causes several
recalcitrant skin infections such as Tinia versicolor, seborrheic
dermatitis and folliculitis. Pro-inflammatory cytokines pro-
duced at infected sites by keratinocytes then induce the in-
flammatory response, and saturated fatty acids released by
yeast lipases stimulate the proliferation of yeast cells (Bukvić
Mokos et al. 2012). Current therapeutic approaches involve
topical formulations containing antifungal and anti-
inflammatory agents, except severe and recalcitrant cases
which require systemic intervention. In the majority of cases,
the first choice treatment is topical azole-type antifungal
agents.
Recalcitrant skin infections caused by M. furfur are com-
monly treated with ketoconazole and/or itraconazole. Howev-
er, certain AMPs are active against M. furfur, including
cathelicidin (López-García et al. 2006). The infection of hu-
man keratinocytes withM. furfur also upregulates endogenous
hBD-2 (Donnarumma et al. 2004). The antifungal and anti-
inflammatory effects of cecropin A(1-8)-magainin 2(1-12) hy-
brid peptide analog P5 againstM. furfurwere reported by Ryu
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et al. (2011). The MIC of P5 against M. furfur was 0.39 μM,
3–4 times higher than ketoconazole and itraconazole. From
the mechanistic point of view, expression of IL-8 and Toll-like
receptor 2, the activation of NF-κB, and the release of intra-
cellular calcium in M. furfur-infected human keratinocytes
were strongly attenuated by treatment with P5. Rev-NIS (nu-
clear entry inhibitory signal peptide of Rev protein), which is a
10-residue derivative of HIV-1 Rev protein also acts against
M. furfur with MIC value of 20 μM (Lee and Lee 2009).
Microorganisms-derived AMPs active
against dermal pathogens
Fungal AMPs also show promising antimicrobial activity. The
acidic hydrophilic heat-stable 0.77 kD peptide A12-C from
Bacillus licheniformis (Glu-Glu-Arg-Ala-Pro-Tyr-Orn) has
been shown to inhibit cell growth and hyphal proliferation in
Mucor plumbeus, Mucor mucedo, and the human dermal
pathogens M. canis and T. mentagrophytes (Gálvez et al.
1993). A12-C is resistant to the proteolytic enzymes pronase,
trypsin, and proteinase K. As well, cryptocandin A is an aro-
matic lipopeptide antifungal agent isolated from the endophyt-
ic fungusCryptosporiopsis cf. quercina, which shows antifun-
gal activity against T. mentagrophytes and T. rubrum with
plate MIC values of 0.035–0.070 μg ml−1 (Strobel et al.
1999). A plate MIC value of 0.035 μg ml−1 was recorded
against C. albicans, making this peptide and its chemical de-
rivatives echinocandin and pneumocandin promising candi-
date therapeutics particularly for the control of human nail
and skin diseases such onychomycosis, tinea pedi, tinea cruris,
tinea corporis, and tinea barbea.
Recently, Huang et al. (2013) reported two active com-
pounds (PE1 and PE2) isolated from Paenibacillus ehimensis
B7, which are active against clinical isolates of E. coli, pan-
drug-resistant P. aeruginosa, and methicillin-resistant
S. aureus.
Insect-derived AMPs
Insects represent the most diverse group of organism on earth.
Their biodiversity at the species level is also reflected by their
diversity of AMPs. The evolutionary success of insects can at
least in part be attributed to their innate immune systems
which display a remarkable plasticity in terms of functional
shifts, diversification, or loss of genes encoding AMPs
(Vilcinskas 2013). The highest number of AMPs in a single
organism, which is more than 50 different AMPs, has been
found in the invasive ladybird Harmonia axyridis (Vilcinskas
et al. 2013). Insect-derived AMPs have been suggested for the
development of novel anti-infectives (Ratcliffe et al. 2011;
Vilcinskas 2013; Yi et al. 2014). Of particular interest for the
development of directly applicable peptides against skin path-
ogens are AMPs from medicinal maggots of the green bottle
fly Lucilia sericata. Their secretions cause remarkable thera-
peutic effects even on chronic and nonhealing wounds which
include the removal of necrotic tissue (debridement), the ac-
celeration of wound healing and wound disinfection (Sherman
2014). The value of medicinal maggots which are also known
as wound maggots in traditional medicine has inspired re-
searchers to identify AMPs produced and secreted by the
maggots. A defensin-like peptide named lucifensin displays
activity against Gram-positive bacteria (Cerovsky et al. 2010).
Another novel peptide from L. sericata which displays exclu-
sive antifungal activities has been named lucimycin (Pöppel
et al. 2014). However, both AMPs are too large to be devel-
oped as short peptidic anti-infectives. Experimental screening
for immune-inducible AMPs using suppression subtractive
hybridization (Altincicek and Vilcinskas 2009) and next-
generation sequencing of the transcriptome from immune-
challenged L. sericata maggots identified 47 genes encoding
putative AMPs including short peptides such as cecropins,
diptericins, proline-rich peptides, and sarcotoxins. Twenty
three of them were produced as synthetic analogs among
which some exhibited activity against a broad spectrum of
microbial pathogens (Pöppel et al. 2015). The easy-to-
synthesize Lucilia-derived AMPs with potent antimicrobial
activity are presently produced in bulk to enable their devel-
opment both as constituents in hydrogels for wound healing
and as cosmetic ingredients to deter dermatological
pathogens.
Skin pathogens can modulate the efficacy of AMPs
C. albicans secretes a large glycofragment of the Msb2 sur-
face protein (Msb2*) into its immediate environment as a
protective decoy for the human AMPs LL-37 and histatin-5
(Swidergall et al. 2013). Likewise, Msb2* can also interact
with human defensins thereby shieldingC. albicans from their
antifungal properties. It also inactivates the lipopeptide antibi-
otic daptomycin, protecting S. aureus, Corynebacterium
pseudodiphteriticum, and E. faecalis. The concurrent cultiva-
tion of S. aureus and wild-type C. albicans (but not the msb2
mutant) resulted in the cross-protection of the bacteria by
Msb2* which attenuated the bactericidal activity of daptomy-
cin and thus incapacitated an important reserve antibiotic
(Swidergall et al. 2013).
Cationic AMPs often work by penetrating the bacterial cell
membrane and altering its transmembrane potential
(Rahnamaeian 2011). Accordingly, sense–response systems
that perceive AMPs and induce adaptive reactions can in-
crease bacterial persistence. In S. aureus, the LytSR two-
component regulatory system may serve as a sensor of trans-
membrane potential. According to Yang et al. (2013), LytSR
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plays a key role in the adaptive response of S. aureus to
membrane-stressing AMPs, perhaps by perceiving slight
changes in transmembrane potential.
Cationic AMPs are sensitive to pH
Walkenhorst et al. (2013) described a family of cationic AMPs
with strong, broad-spectrum activity at neutral pH and low
ionic strength. The efficacy of these peptides against an array
of microbes varied linearly with pH for each subtype, i.e. they
were far less effective against C. albicans and Gram-negative
bacteria at high pH values, reflecting the decline in net posi-
tive charge. Interestingly, a reverse pH trend was observed for
their activity against the Gram-positive bacterium S. aureus,
probably reflecting the presence of charged molecules in the
peptidoglycan layer of the cell wall. The buffer pH and ionic
strength showed an additive effect on AMP activity
(Walkenhorst et al. 2013).
Multiple AMPs can interact to maximize their
antimicrobial potency
The synergy of AMPs and antibiotics has been frequently
reported. For instance, Ranalexin is a cationic peptide 20 res-
idues in length isolated from Rana catesbeiana, which is ac-
tive against S. aureus, S. pyogenesis, methicillin-resistant
S. aureus, and C. albicans with a MIC value of 8 μg ml−1
(Aleinein et al. 2013); however, when combined with poly-
myxin B or linezolid, the MIC value is reduced by 75 %
(Aleinein et al. 2014). As well, epinecidin-8 and pardaxin-6
work in synergy with streptomycin and kanamycin to increase
their potency up to 75% against methicillin-resistant S. aureus
(Lin et al. 2013). Nonetheless, the potentiation between natu-
rally co-occurring AMPs has been almost neglected. We have
recently shown that the concurrent application of multiple
AMPs can increase the overall antimicrobial potency in a
more than additive manner (Rahnamaeian et al. 2015; Pöppel
et al. 2015). In nature, microbial challenge elicits a cocktail of
AMPs in response (Rahnamaeian and Vilcinskas 2012;
Vilcinskas et al. 2013). These AMPs usually have diverse
modes of action so that they complement rather than replicate
each other. For example, the insect AMPs abaecin and
hymenoptaecin work cooperatively to inhibit the proliferation
of E. coli at low MICs (Rahnamaeian et al. 2015). Abaecin
shows no antimicrobial activity when presented alone because
it needs to gain entry into the cell to interact with the bacterial
chaperone DnaK, whereas hymenoptaecin is only active at
high concentrations because its mechanism as a sole agent is
based on the dose-dependent perforation of the bacterial mem-
brane. However, when both AMPs are present together,
hymenoptaecin creates pores that allow abaecin to access the
cell and bind to DnaK, and this in turn inhibits the bacterial
mechanisms that repair membrane damage allowing
hymenoptaecin to compromise the cell more rapidly. A similar
synergistic activity has also been observed among particular
AMPs produced and secreted by medicinal maggots
L. sericata (Pöppel et al. 2015). Because the antimicrobial
properties of AMPs can be resolved to shorter motifs, the
synthesis of hybrid peptides encompassing the functional mo-
tifs of several AMPs could provide robust protection against
microbial pathogens by combining the beneficial properties of
multiple AMPs into one therapeutic entity.
Organometallic derivatives of short AMPs
The organometallic derivation of existing short AMPs has the
potential to (i) increase the potency of AMPs and (ii) provide
metal-specific modes of action that delay the acquisition of
resistance by bacterial populations. The typical classes of or-
ganometallic compounds are metallocene, M-arene, M-car-
bonyl, and M-carbene (Fig. 1). The activity of ferrocenoyl-
derivatized AMPs predominantly reflects the lipophilic prop-
erties of the organometallic fragment (Albada et al. 2013). The
L-to-D substitution of amino acid residues in short lipidated
AMPs can also produce diastereomeric peptides with opti-
mized antimicrobial potency and reduced hemolytic activity
(Albada et al. 2013). The structural diversity and potential
catalytic properties of organometallic AMP derivatives and
their availability for ligand exchange and redox reactions
(Gasser and Metzler-Nolte 2012) may contribute to their de-
velopment as cosmetic ingredients. Generally, transition
metals of the second and third rows of the periodic table with
closed electron shells, e.g., ruthenium (Ru), osmium (Os), and
Fig. 1 Classic groups of the organometallics used in medicinal
chemistry. a Metal-carbene. b Metallocene. c Metal-arene. d Metal-
carbonyl (in different variants). M indicates the metal element
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iridium (Ir), are the most proper cases to be recruited in me-
dicinal inorganic chemistry (Gasser and Metzler-Nolte 2012).
Conclusion
Although AMPs have only been tested in a small number of
clinical trials, there is adequate proof-of-concept to support
their use as topical anti-infectives. Antimicrobials and their
derivatives are unlikely to replace conventional antibiotics
because they cannot be administered orally or by injection,
but they are ideal for topical applications and could be used
as pharmaceuticals to treat skin infections as well as cosmetic
ingredients to deter skin pathogens and maintain skin health.
The diverse spectrum of antimicrobial activities demonstrated
by different AMPs, and the ease with which short AMPs can
be synthesized and modified, make them promising candi-
dates for the development of cosmetic products that deter der-
matological pathogens.
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